Mustang Bio, Inc. (MBIO)
Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for cancer and rare diseases. Established to leverage innovative scientific advancements, the company aims to deliver targeted treatments with the potential for durable responses in patients with unmet medical needs.
Company News
Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.
Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.
Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.
Use these top tips to navigate the bull and bear penny stocks market The post Navigating Bull and Bear Penny Stocks Markets, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.